Plasma cell isolation
Unleash the power of innovation
CD138+ Plasma Cell Isolation Redefined
The expression of CD138, a marker expressed on the surface of plasma cells, plays a critical role in the identification of plasma cell tumors and multiple myeloma cells.1 While the characteristics of plasma cells can vary depending on the disease stage and biological traits of the patient, studies have proven the prognostic value of specific antigen expression patterns in neoplastic plasma cells.2
Traditionally, the assessment of plasma cells in bone marrow involves a time-consuming and labor-intensive method involving ficoll density gradient separation, which results in the loss of antigens, including CD138, from the plasma cell surface, necessitating immediate staining and analysis.2 MARS® platform incorporates their proprietary in-flow immuno-magnetic separation technology to efficiently isolate CD138+ plasma cells directly from unprocessed bone marrow samples. This innovative approach simplifies the isolation process, enabling fast and dependable analysis of CD138 expression in plasma cells.
The efficient isolation of CD138+ plasma cells can be pivotal for various clinical and therapeutic research applications. This includes developing new tools for in diagnosing, prognosing and treatment of multiple myeloma, eg. with FISH or Next-Generation Sequencing. In autoimmune diseases, CD138+ plasma cells are investigated due to their role in producing autoantibodies. They are also of interest in vaccine, immunity, immunodeficiency disorders or bone marrow transplantation research and development.
1. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999;12(12): 1101-1106.
2. Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010 Sep;23(3):433-51.
MARS® platform: Transforming Challenges into Solutions
The MARS® platform utilizes an exceptional in-flow technology that eliminates the need for columns. This feature offers flexibility in optimizing workflows to achieve the highest possible purity and recovery rates. Furthermore, the absence of a matrix allows users to directly isolate target cells (even at low percentages) from unprocessed samples, such as peripheral blood, bone marrow, and cord blood.
automatic 2x or 3x separation guarantees unmatched consistency and a seamless user experience
far superior to conventional methods, our technology ensures high cell purity and recovery that consistently outperforms
reusable and cleanable fluidics dramatically reduces the cost, while pre-set cleaning protocols offer unprecedented efficiency
CD138+ Cell Isolation
Directly from Bone Marrow
CD138 expression is important in diagnosing plasma cell tumors and multiple myeloma. This application note highlights the MARS® platform as an innovative tool for efficiently isolating CD138+ plasma cells from bone marrow samples. This streamlined approach facilitates rapid and reliable isolation of plasma cells, revolutionizing the research for plasma cell-related disorders.
Easy, sequential purification process
The MARS® platform simplifies the cell isolation process through its fast and easy workflow, which improves purity while maintaining high recovery of cells. Our instrument uses an automated one- to three-pass cell enrichment process and involves minimal hands-on time.
Other unique features include matrix-free cell isolation, economical consumables, and sterilizable and reusable fluidics. The obtained samples can also be rapidly re-run through the magnetic channel to maximize efficiency.